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Abstract We examined whether the W opioid receptor was
palmitoylated and attempted to determine sites of palmitoyla-
tion. Following metabolic labeling with [3H]palmitic acid and
immunoaffinity purification of the W opioid receptor, SDS-
PAGE and fluorography revealed a broad labeled band with Mr
of V80 kDa in CHO cells stably expressing the rat W receptor,
but not in CHO cells transfected with the vector alone, indicating
that the W receptor is palmitoylated. Activation of the receptor
with morphine did not affect the extent of palmitoylation.
Hydroxylamine or dithiothreitol treatment removed most of the
radioactivity, demonstrating that [3H]palmitic acid is incorpo-
rated into Cys residue(s) via thioester bond(s). Surprisingly,
mutations of the only two Cys residues in the C-terminal domain
did not reduce [3H]palmitic acid incorporation significantly.
Thus, unlike many G-protein coupled receptors, the palmitoyla-
tion site(s) of the rat W opioid receptor do(es) not reside in the C-
terminal domain.
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1. Introduction
Mu opioid receptors play important roles in many physio-
logical functions, most notably modulation of pain perception
and regulation of mood (for a review [1]). Analgesic e¡ects of
many opiates and opioids are mediated primarily by W opioid
receptors. Opiates (such as morphine and heroin) are among
the most widely abused drugs, mainly because of their actions
on the W opioid receptor to induce euphoria. Development of
tolerance to and dependence on opiates is mediated largely by
the W receptor. Activation of W opioid receptors couples via
pertussis toxin-sensitive G proteins to various e¡ectors, in-
cluding adenylate cyclase and K and Ca2 channels (for a
review, [2]) and mitogen-activated kinase [3]. Following the
cloning of a mouse N opioid receptor [4,5], W receptors were
cloned [6^8]. A splice variant of the W receptor was reported
with sequence variation at the last few amino acids of the C-
terminal domain [9,10]. Deduced amino acid sequences of
these clones display the motif of seven transmembrane helices,
which is characteristic of G-protein coupled receptors
(GPCRs).
Many GPCRs have been shown to be covalently modi¢ed
by palmitic acid (for a review [11]), including rhodopsin [12^
14], L2-adrenergic [15,16], K2A-adrenergic [17], luteinizing hor-
mone/human choriogonadotropin [18,19], endothelin A [20],
serotonin1B [21], dopamine D1 [22], dopamine D2L [23], dop-
amine D2S [24], mGluR4 metabotropic glutamate [25] and
thyrotropin [26] receptors. The sites for palmitoylation were
determined to be conserved cysteine residues in the proximal
portion of the C-terminal domain in a few GPCRs, including
rhodopsin [13,14] and L2-adrenergic [15], K2A-adrenergic [17],
luteinizing hormone/human choriogonadotropin [18,19], en-
dothelin A [20] and thyrotropin [26] receptors. Alignment of
74 GPCRs, including receptors mediating diverse signal trans-
duction pathways, shows that V78% have a cysteine at this
position [27]. Both splice variants of the W receptor also have a
conserved cysteine at this position. Using £uorescent palmi-
tate derivative, Moench et al. [28] demonstrated that the pal-
mitoylation sites of rhodopsin were embedded in the mem-
brane, thus forming a small fourth cytoplasmic loop in the
C-terminal domain. Similar topology was postulated for other
receptors [13,15,29]. However, palmitoylation appears to play
diverse functional roles among GPCRs, such as coupling to
G-proteins [15,30], or agonist-induced receptor desensitization
[15,31], phosphorylation [31], internalization [18,26,32] or
down-regulation [33].
In this study, we examined incorporation of [3H]palmitic
acid into the rat W opioid receptor [6], the e¡ect of morphine
stimulation on palmitoylation of the W receptor and the nature
of the chemical bond formed between palmitic acid and the W
receptor. In addition, we examined palmitoylation of two mu-
tant W receptors, C351A and C346A/C351A, since Cys-346
and Cys-351 reside in the proximal portion of the C-terminal
domain and are the only two cysteine residues in the C-ter-
minal domain.
2. Materials and methods
2.1. Materials
[3H]Diprenorphine (58 Ci/mmol) and [3H]palmitic acid (V50 Ci/
mmol) were purchased from NEN Life Science (Boston, MA). Mor-
phine and [3H]L-funaltrexamine ([3H]L-FNA) (19 Ci/mmol) were pro-
vided by the National Institute on Drug Abuse. Naloxone was a gift
from DuPont/Merck Co. (Wilmington, DE). Muta-Gene kit was pur-
chased from Bio-Rad Co. (Hercules, CA); Lipofectamine from Gibco
BRL (Gaithersburg, MD); peptide-N4-[N-acetyl-L-glucosaminyl]as-
paragine amidase (N-glycanase) from Genzyme Co. (Boston, MA);
silica gel thin layer chromatography (TLC) plates from Analtech
Inc. (Newark, DE); NP-40 from Pierce Co. (Rockford, IL); Seque-
nase version 2.0 from USB Biochemicals (Cleveland, OH); geneticin,
protease inhibitors and other commonly used chemicals from Sigma.
2.2. Labeling with [3H]palmitic acid and solubilization
CHO cells stably expressing the rat W receptor [6] were examined for
palmitoylation according to a modi¢ed procedure of O’Dowd et al.
[15]. CHO cells transfected with the vector pRc/CMV served as the
control. Twenty-four hours before labeling, cells were plated at
V80% density in 100 mm dishes. After washed once with serum-
free medium, cells were incubated in 5 ml serum-free medium per
dish with 0.2 mCi/ml [3H]palmitic acid for 4 h. For examination of
the e¡ect of morphine, 2 WM morphine was added to cells 1 h before
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termination of the labeling. Labeled cells were then detached in Ver-
sene solution (0.67 mM EDTA, 136.9 mM NaCl, 2.7 mM KCl, 8.1
mM Na2HPO4, 1.5 mM KH2PO4 and 1.1 mM glucose, pH 7.0),
collected by centrifugation and washed twice with ice-cold Versene.
The cells were sonicated for 10 s in ice-cold bu¡er A (2% NP-40, 0.1
M Tris-HCl, pH 7.0, 0.1 M NaCl, 10 Wg/ml of each of the protease
inhibitors aprotinin, leupeptin, pepstatin A and soybean trypsin in-
hibitor, 1 mM ethylenediaminetetraacetic acid and 1 mM phenylme-
thylsulfonyl £uoride) and left on ice for 30^60 min to complete sol-
ubilization. The lysate was centrifuged at 40 000Ug for 20 min at 4‡C
and the supernatants were ¢ltered through a 0.22 Wm ¢lter.
2.3. Immunoa⁄nity puri¢cation of labeled W opioid receptor
Immunoa⁄nity puri¢cation of labeled W opioid receptor using rab-
bit antiserum against the C-terminal peptide 383^398 (CTNHQLEN-
LEAETAPLP) was performed according to our published procedures
[34].
2.4. TLC of [3H]fatty acid associated with the immunoa⁄nity-puri¢ed
rat W opioid receptor
These experiments were conducted according to the method of
O’Dowd et al. [15]. The immunoa⁄nity-puri¢ed labeled receptor
was acidi¢ed with HCl to pH 1.0 and extracted three times with ethyl
acetate and three times with hexane to remove free [3H]palmitic acid.
The aqueous phase was then treated with 1 N KOH for 12 h at 37‡C,
followed by acidi¢cation and extraction as above. The extract was
dried under N2 and applied to a silica gel TLC plate along with
authentic [3H]palmitic acid in a parallel lane. The TLC plate was
developed with hexane:ethyl acetate:acetic acid (80:20:1), cut into
1 cm fractions, and the radioactivity in each fraction determined by
liquid scintillation counting.
2.5. Treatment of [3H]palmitate-labeled W receptor with
hydroxylamine or dithiothreitol (DTT)
Immunoa⁄nity-puri¢ed [3H]palmitate-labeled receptor was incu-
bated with 1 M NH2OH or 0.1 M DTT at pH 7.5 in 2% sodium
dodecyl sulfate (SDS) at 37‡C for 30 min for NH2OH treatment
[12,14,35] and for 2 h for DTT treatment [14]. The reaction mixture
was acidi¢ed with 1/10 volume of 1 N HCl and extracted with an
equal volume of ethyl acetate four times to remove free [3H]palmitate.
The aqueous phase was counted for radioactivity. For SDS-polyacryl-
amide gel electrophoresis (SDS-PAGE) analysis, the treated prepara-
tions were loaded onto SDS-PAGE without ethyl acetate extraction.
2.6. Oligodeoxynucleotide-directed mutagenesis
Mutations were generated on the rat W receptor with the uracil
replacement method of Kunkel et al. [36] using Muta-Gene kit.
The primers used to introduce mutations were: CTTCAAGC-
GAGCCTTCAGAGAG (C346A); CAGAGAGTTCGCCATCCCA-
ACC (C351A); TCAAGAGAGCCTTCAGAGAGTTCGCCATCC-
CAAC (C346A/C351A)
Mutations were con¢rmed by DNA sequence determination with
the method of Sanger et al. [37].
2.7. Other methods employed
The following methods were described in our previous publications:
stable expression of the W receptor in CHO cells [38], labeling of W
opioid receptors with [3H]L-FNA [38], SDS-PAGE and detection of
radioactivity in gels by £uorography [39], N-glycanase treatment [39]
and protein determinations [38,40].
3. Results and discussion
We ¢rst examined whether [3H]palmitic acid was incorpo-
rated in the rat W opioid receptor. CHO-WR cells (W66), which
stably express approximately 10 pmol/mg protein of the rat W
opioid receptor, were used. Similar numbers of CHO-WR
(W66) and CHO cells transfected with the vector pRc/CMV
were labeled with [3H]palmitic acid. Membranes were pre-
pared, solubilized and the W receptor was partially puri¢ed
using immunoa⁄nity chromatography. SDS-PAGE of the im-
munoa⁄nity-puri¢ed material and subsequent £uorography
revealed a broad and di¡use labeled protein band with Mr
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Fig. 1. Incorporation of [3H]palmitic acid into the W opioid receptor
stably expressed in CHO cells. Incubation of CHO-WR cells or
CHO cells transfected with the vector pRc/CMV with [3H]palmitic
acid and immunoa⁄nity chromatography were performed as de-
scribed in Section 2. Lanes 1 and 2: immunoa⁄nity-puri¢ed materi-
als from [3H]palmitic acid-labeled CHO-WR cells (40 000 dpm, V5
Wg protein) and CHO cells transfected with the vector pRc/CMV
(20 000 dpm, V5 Wg protein), respectively. This ¢gure represents
one of two experiments. Exposure time was 7 days.
Fig. 2. Deglycosylation by N-glycanase of immunoa⁄nity-puri¢ed
[3H]L-FNA-labeled W opioid receptors and [3H]palmitate-labeled ma-
terials in solubilized CHO-WR membranes. [3H]L-FNA-labeled W
opioid receptors and [3H]palmitate-labeled materials in solubilized
CHO-WR membranes were treated with or without N-glycanase (1
unit) at 37‡C for 6 h and subjected to SDS-PAGE and £uorogra-
phy. Lanes 1 and 3: [3H]L-FNA-labeled W opioid receptors, control
and N-glycanase-treated, respectively, 37 000 dpm and V0.8 pmol
of W receptors each. Lanes 2 and 4: [3H]palmitate-labeled materials,
control and N-glycanase-treated, respectively, 20 000 dpm and V2
pmol of receptor each. This experiment was performed twice with
the same results. Exposure time was 7 days.
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V80 kDa present in the CHO-WR preparation, but not in the
preparation of CHO cells transfected with the vector pRc/
CMV alone (Fig. 1), despite the fact that the two preparations
showed similar levels of total [3H]palmitic acid incorporation.
The broad and di¡use pattern of the labeled protein band
indicates its glycoprotein nature. Following deglycosylation
by N-glycanase, the labeled protein band became a relatively
sharp band of Mr V40 kDa (Fig. 2), which is in accordance
with the deduced molecular weight of the rat W receptor [6].
This labeled band was identical to [3H]L-FNA-labeled rat W
receptor (Fig. 2) in its Mr and electrophoretic properties.
These results indicate that the rat W receptor in CHO-WR cells
is palmitoylated.
Since [3H]palmitic acid can be metabolized to other fatty
acids, we examined whether it was [3H]palmitic acid that was
incorporated into the rat W opioid receptor. The [3H]fatty acid
released from puri¢ed labeled material by alkali treatment had
an identical migration distance to that of authentic
[3H]palmitic acid in silica gel TLC analysis, indicating that
the receptor is acylated with [3H]palmitic acid (Fig. 3).
Exposure to isoproterenol led to a speci¢c increase in the
incorporation of palmitic acid in the L2-adrenergic receptor
[41]. We determined if palmitoylation of the rat W receptor
was a¡ected by morphine. As shown in Fig. 4, exposure
to 2 WM morphine for 1 h did not a¡ect signi¢cantly
[3H]palmitate incorporation into the rat W receptor. The X-
ray ¢lms of two independent experiments were scanned and
the area of each band was integrated by use of NIH Image
software program. The extents of palmitoylation of morphine-
treated W receptors represented 105% and 82% (mean = 93.5%)
of the control levels. Thus, palmitoylation of the rat W recep-
tor appears not to be a¡ected by morphine.
Hydroxylamine and DTT treatments of [3H]palmitate-la-
beled W opioid receptor were performed to determine whether
the chemical bond(s) formed between [3H]palmitic acid and
the W receptor were thioester in nature or involved thiol
group. Hydroxylamine (1 M) or DTT (0.1 M) removed
[3H]palmitate from labeled W opioid receptor by 75% and
85%, respectively (Fig. 5A). SDS-PAGE and £uorography
showed that labeling of the W receptor was greatly reduced
by hydroxylamine or DTT (Fig. 5B). Since the chemicals and
the conditions used speci¢cally cleaved thioester bonds, these
results demonstrated that [3H]palmitic acid was incorporated
into one or multiple cysteine residues.
There are two cysteines, C346 and C351, present in the
proximal portion of the C-terminal domain in the rat W opioid
receptor. One or two highly conserved cysteines in this region
have been shown to be palmitoylated in a few GPCRs [13^
15,17^20,26]. We replaced the two cysteines with alanines,
individually and in combination, and expressed the mutant
receptors stably in CHO cells. The expression levels of
C346A, C351A and C345A/C351A mutants were determined
by [3H]diprenorphine binding and the clones with highest ex-
pression levels contained 0.2, 4.5 and 1.5 pmol/mg protein,
respectively. Kd values of [3H]diprenorphine binding to the
mutants were not signi¢cantly di¡erent from that of the wild-
type. The low expression levels of C346A made it impossible
to examine its palmitoylation. Palmitoylation of C351A and
C346A/C351A mutant receptors was investigated and com-
pared to that of the wildtype. For the C351A mutant, W66
cells were used. For the C346A/C351A mutant, another CHO-
WR cell line (W1), which expresses V2.5 pmol/mg protein of
the wildtype receptor, was used as the control to avoid com-
plication in data interpretation due to the vast di¡erence in
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Fig. 3. Thin-layer chromatography of [3H]fatty acid associated with
the immunoa⁄nity-puri¢ed rat W opioid receptor. Immunoa⁄nity-
puri¢ed [3H]labeled rat W opioid receptor was subjected to alkali
treatment and the released radioactivity was analyzed on silica gel
TLC along with authentic [3H]palmitic acid as described in Section
2. The ¢gure shows the migration distance of radioactivity released
from a⁄nity-puri¢ed labeled rat W opioid receptor, with the arrows
indicating that of authentic [3H]palmitic acid (about 1/3 at 4 cm
and 2/3 at 5 cm).
Fig. 4. E¡ect of morphine stimulation on palmitoylation of the rat
W opioid receptor. Similar numbers of CHO-WR cells were labeled
with [3H]palmitic acid with or without morphine treatment and la-
beled receptors partially puri¢ed and subjected to SDS-PAGE and
£uorography. Lane 1: [3H]palmitic acid-labeled CHO-WR cells (V2
pmol receptors, 15 000 dpm); lane 2: [3H]palmitic acid-labeled
CHO-WR cells with 2 WM morphine added 1 h before termination
of the labeling (V2 pmol receptors, 16 000 dpm). Exposure time
was 20 days.
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expression level. To our surprise, both C351A and C346A/
C351A mutant receptors were palmitoylated to similar extents
as the wildtype receptor (Fig. 6). We con¢rmed the presence
of desired mutations and the absence of unwanted mutations
in C351A and C346A/C351A mutants stably transfected into
CHO cells by performing reverse transcription-polymerase
chain reaction on poly(A) RNA and DNA sequence deter-
mination of the product. Our results indicate that neither of
the only two Cys residues in the C-terminal domain is the
palmitoylation site. Thus, palmitoylation may occur at cys-
teine residues outside of the C-terminal domain. This ¢nding
is at odds with the observations that palmitoylation sites of
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Fig. 5. Depalmitoylation of [3H]palmitic acid-labeled W receptors with DTT or hydroxylamine. A: Immunoa⁄nity-puri¢ed [3H]palmitic acid-la-
beled W receptors were incubated with or without DTT for 2 h or hydroxylamine for 30 min, extracted with ethyl acetate and the aqueous
phase counted for radioactivity as described in Section 2. Data are expressed as % of the control. This experiment was repeated three times
with similar results. B: SDS-PAGE (7%) and £uorography. Approximately 10 pmol each of immunoa⁄nity-puri¢ed labeled receptors were
treated under the same conditions as in A and loaded onto the gel. Lane 1: control. Lane 2: 0.1 M DTT. Lane 3: 1 M hydroxylamine. This
¢gure represents one of the two experiments performed with similar results. Exposure time was 7 days.
Fig. 6. E¡ects of (A) C351A and (B) C346A/C351A mutations on [3H]palmitic acid incorporation into the W receptor. CHO-WR cells, CHO-
C351A cells and CHO-C346A/C351A cells were labeled with [3H]palmitic acid, solubilized and labeled receptors puri¢ed with immunoa⁄nity
chromatography. Eluates were subjected to SDS-PAGE and £uorography. A: Lane 1: [3H]palmitic acid-labeled CHO-WR cells (W66 cells) (V6
pmol receptors, 54 000 dpm); lane 2: [3H]palmitic acid-labeled CHO-C351A cells (V7 pmol receptors, 62 000 dpm). B: Lane 3: [3H]palmitic
acid-labeled CHO-WR cells (W1 cells) (V2 pmol receptors, 18 000 dpm); lane 4: [3H]palmitic acid-labeled CHO-C346A/C351A cells (V2.5 pmol
receptors, 23 000 dpm). This ¢gure represents one of two (A) or three (B) experiments with similar results. Exposure time was 7 days (A) or 20
days (B).
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rhodopsin [13,14] and L2-adrenergic [15], K2A-adrenergic [17],
luteinizing hormone/human choriogonadotropin [18,19], en-
dothelin A [20] and thyrotropin [26] receptors are cysteine
residues in the proximal portion of the C-terminal domain.
However, our results are in accord with recent ¢ndings on
serotonin1B and serotonin1D receptors by O’Dowd et al.
[42]. The serotonin1D receptor was shown to be palmitoylated
despite of its lack of cysteine residues in the C-terminal do-
main. The serotonin1B receptor was palmitoylated; however, a
mutant in which the only cysteine residue in the C-terminal
domain was substituted with alanine was still palmitoylated.
Cys-170 in the second intracellular loop is the only other
cysteine residue in the intracellular domains of the rat W re-
ceptor. C170A and C170A/C346A/C351A mutants were gen-
erated. However, both mutants exhibited very low level of
[3H]diprenorphine binding and immunohistochemical staining
of the W opioid receptor (not shown). Therefore, we did not
examine palmitoylation of these mutants.
In our experience, an expression level of approximately 1.5
pmol receptor/mg protein is the detection limit for
[3H]palmitic acid incorporation. This limit is imposed by the
speci¢c activity of [3H]palmitic acid, which is lowered further
by the endogenous palmitate. Many previous palmitoylation
studies on GPCRs were conducted on mammalian cells with
high receptor expression levels [14,15,18,20,25,43]. In more
recent years, the baculovirus-Sf9 cell expression system, which
usually gives a high level of expression, was used in some
palmitoylation studies [21^23,41]. We opted to use CHO cells
instead of the baculovirus-Sf9 cell expression system for two
reasons. First, mammalian cells are more physiologically rel-
evant. Second, the human or mouse W opioid receptor has
been expressed using the baculovirus-Sf9 cell or ‘High Five’
cell system and the expression level is not higher than what we
observed in CHO cells [44,45].
In conclusion, the rat W opioid receptor expressed in CHO
cells undergoes palmitoylation and morphine treatment did
not a¡ect the level of palmitoylation. [3H]Palmitic acid is in-
corporated via thioester bond(s) into Cys residue(s) ; however,
it appears that neither Cys-346 nor Cys-351, the only two Cys
residues in the C-terminal domain, is the site of palmitic acid
incorporation.
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